伊必那班

**伊必那班**
臨床資料
ATC碼	未分配;
識別資訊
	IUPAC命名法 4S-(−)-3-(4-chlorophenyl)-N-methyl-N'-[(4-chlorophenyl)-sulfonyl]-4-phenyl-4,5-dihydro-1H-pyrazole-1-carboxamidine; ;
CAS號	464213-10-3
PubChem CID	9826744;
ChemSpider	24765166 ;
UNII	O5CSC6WH1T;
KEGG	D09349 ;
ChEMBL	ChEMBL158784 ;
CompTox Dashboard（英語：CompTox Chemicals Dashboard） (EPA)	DTXSID70963572 ;
ECHA InfoCard	100.158.931
化學資訊
化學式	C24H22Cl2N4O2S
摩爾質量	501.427
3D模型（JSmol（英語：JSmol））	交互式圖像;
	SMILES c2cc(Cl)ccc2C1=NN(C(NC)=NCS(=O)(=O)c3ccc(Cl)cc3)CC1c4ccccc4;
	InChI InChI=1S/C24H22Cl2N4O2S/c1-27-24(28-16-33(31,32)21-13-11-20(26)12-14-21)30-15-22(17-5-3-2-4-6-17)23(29-30)18-7-9-19(25)10-8-18/h2-14,22H,15-16H2,1H3,(H,27,28)/t22-/m1/s1 ; Key:BSFKAVCGRDMWTK-JOCHJYFZSA-N ;

伊必那班（英語：Ibipinabant；開發代號：SLV319、BMS-646,256) 是一種用於科學研究的藥物，可作為強效和高選擇性的大麻素受體1（CB₁）拮抗劑。^[1]它對動物有強烈的厭食作用，^[2]並被研究用於治療肥胖症，CB₁拮抗劑作為一類藥物由於利莫那班出現的問題而不再受青睞，因此伊比那班現在僅用於實驗室研究，特別是對新型CB₁拮抗劑的構效關係研究。^[3]^[4]^[5]SLV330是伊必那班的結構類似物，據報道其在與記憶、認知以及成癮行為調節相關的動物模型中具有活性。^[6]^[7]已報道了伊必那班的原子效率合成。^[8]

參見[編輯]

大麻素受體拮抗劑

參考資料[編輯]

^ Lange JH, Coolen HK, van Stuivenberg HH, Dijksman JA, Herremans AH, Ronken E, et al. Synthesis, biological properties, and molecular modeling investigations of novel 3,4-diarylpyrazolines as potent and selective CB(1) cannabinoid receptor antagonists. Journal of Medicinal Chemistry. January 2004, 47 (3): 627–43. PMID 14736243. doi:10.1021/jm031019q.
^ Need AB, Davis RJ, Alexander-Chacko JT, Eastwood B, Chernet E, Phebus LA, et al. The relationship of in vivo central CB1 receptor occupancy to changes in cortical monoamine release and feeding elicited by CB1 receptor antagonists in rats. Psychopharmacology. January 2006, 184 (1): 26–35. PMID 16328376. S2CID 23402768. doi:10.1007/s00213-005-0234-x.
^ Lange JH, van Stuivenberg HH, Veerman W, Wals HC, Stork B, Coolen HK, et al. Novel 3,4-diarylpyrazolines as potent cannabinoid CB1 receptor antagonists with lower lipophilicity. Bioorganic & Medicinal Chemistry Letters. November 2005, 15 (21): 4794–8. PMID 16140010. doi:10.1016/j.bmcl.2005.07.054.
^ Srivastava BK, Joharapurkar A, Raval S, Patel JZ, Soni R, Raval P, et al. Diaryl dihydropyrazole-3-carboxamides with significant in vivo antiobesity activity related to CB1 receptor antagonism: synthesis, biological evaluation, and molecular modeling in the homology model. Journal of Medicinal Chemistry. November 2007, 50 (24): 5951–66. PMID 17979261. doi:10.1021/jm061490u.
^ Srivastava BK, Soni R, Joharapurkar A, Sairam KV, Patel JZ, Goswami A, et al. Bioisosteric replacement of dihydropyrazole of 4S-(-)-3-(4-chlorophenyl)-N-methyl-N'-[(4-chlorophenyl)-sulfonyl]-4-phenyl-4,5-dihydro-1H-pyrazole-1-caboxamidine (SLV-319) a potent CB1 receptor antagonist by imidazole and oxazole. Bioorganic & Medicinal Chemistry Letters. February 2008, 18 (3): 963–8. PMID 18207393. doi:10.1016/j.bmcl.2007.12.036.
^ de Bruin, NMWJ; Prickaerts, J; Lange, JHM; Akkerman, S; Andriambeloson, E; de Haan, M; Wijnen, J; van Drimmelen, M; Hissink, E; Heijink, L; Kruse, CG. SLV330, a cannabinoid CB1 receptor antagonist, ameliorates deficits in the T-maze, object recognition and Social Recognition Tasks in rodents. Neurobiology of Learning and Memory. 2010, 93 (4): 522–531. PMID 20132903. S2CID 207261719. doi:10.1016/j.nlm.2010.01.010 （英語）.
^ de Bruin, NMWJ; Lange, JHM; Kruse, CG; Herremans, AH; Schoffelmeer, ANM; van Drimmelen, M; De Vries, TJ. SLV330, a cannabinoid CB1 receptor antagonist, attenuates ethanol and nicotine seeking and improves inhibitory response control in rats. Behavioural Brain Research. 2011, 217 (2): 408–415. PMID 21074574. S2CID 205882042. doi:10.1016/j.bbr.2010.11.013 （英語）.
^ Lange, JHM; Sanders, HJ; van Rheenen, J. An expedient atom-efficient synthesis of the cannabinoid CB1 receptor inverse agonist ibipinabant. Tetrahedron Letters. 2011, 52 (12): 1303–1305. ISSN 0040-4039. doi:10.1016/j.tetlet.2011.01.068 （英語）.

[1] Lange JH, Coolen HK, van Stuivenberg HH, Dijksman JA, Herremans AH, Ronken E, et al. Synthesis, biological properties, and molecular modeling investigations of novel 3,4-diarylpyrazolines as potent and selective CB(1) cannabinoid receptor antagonists. Journal of Medicinal Chemistry. January 2004, 47 (3): 627–43. PMID 14736243. doi:10.1021/jm031019q.

[2] Need AB, Davis RJ, Alexander-Chacko JT, Eastwood B, Chernet E, Phebus LA, et al. The relationship of in vivo central CB1 receptor occupancy to changes in cortical monoamine release and feeding elicited by CB1 receptor antagonists in rats. Psychopharmacology. January 2006, 184 (1): 26–35. PMID 16328376. S2CID 23402768. doi:10.1007/s00213-005-0234-x.

[3] Lange JH, van Stuivenberg HH, Veerman W, Wals HC, Stork B, Coolen HK, et al. Novel 3,4-diarylpyrazolines as potent cannabinoid CB1 receptor antagonists with lower lipophilicity. Bioorganic & Medicinal Chemistry Letters. November 2005, 15 (21): 4794–8. PMID 16140010. doi:10.1016/j.bmcl.2005.07.054.

[4] Srivastava BK, Joharapurkar A, Raval S, Patel JZ, Soni R, Raval P, et al. Diaryl dihydropyrazole-3-carboxamides with significant in vivo antiobesity activity related to CB1 receptor antagonism: synthesis, biological evaluation, and molecular modeling in the homology model. Journal of Medicinal Chemistry. November 2007, 50 (24): 5951–66. PMID 17979261. doi:10.1021/jm061490u.

[5] Srivastava BK, Soni R, Joharapurkar A, Sairam KV, Patel JZ, Goswami A, et al. Bioisosteric replacement of dihydropyrazole of 4S-(-)-3-(4-chlorophenyl)-N-methyl-N'-[(4-chlorophenyl)-sulfonyl]-4-phenyl-4,5-dihydro-1H-pyrazole-1-caboxamidine (SLV-319) a potent CB1 receptor antagonist by imidazole and oxazole. Bioorganic & Medicinal Chemistry Letters. February 2008, 18 (3): 963–8. PMID 18207393. doi:10.1016/j.bmcl.2007.12.036.

[6] Bruin, NMWJ; Prickaerts, J; Lange, JHM; Akkerman, S; Andriambeloson, E; de Haan, M; Wijnen, J; van Drimmelen, M; Hissink, E; Heijink, L; Kruse, CG. SLV330, a cannabinoid CB1 receptor antagonist, ameliorates deficits in the T-maze, object recognition and Social Recognition Tasks in rodents. Neurobiology of Learning and Memory. 2010, 93 (4): 522–531. PMID 20132903. S2CID 207261719. doi:10.1016/j.nlm.2010.01.010 （英語）.

[7] Bruin, NMWJ; Lange, JHM; Kruse, CG; Herremans, AH; Schoffelmeer, ANM; van Drimmelen, M; De Vries, TJ. SLV330, a cannabinoid CB1 receptor antagonist, attenuates ethanol and nicotine seeking and improves inhibitory response control in rats. Behavioural Brain Research. 2011, 217 (2): 408–415. PMID 21074574. S2CID 205882042. doi:10.1016/j.bbr.2010.11.013 （英語）.

[8] Lange, JHM; Sanders, HJ; van Rheenen, J. An expedient atom-efficient synthesis of the cannabinoid CB1 receptor inverse agonist ibipinabant. Tetrahedron Letters. 2011, 52 (12): 1303–1305. ISSN 0040-4039. doi:10.1016/j.tetlet.2011.01.068 （英語）.

[1]

[2]

[3]

[4]

[5]

[6]

[7]

[8]